Bio-View Ltd (TLV:BIOV)

Market Cap	21.58M -43.4%
Revenue (ttm)	19.93M -22.3%
Net Income	-15.33M
EPS	-0.11
Shares Out	134.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,292
Average Volume	213,210
Open	16.10
Previous Close	16.10
Day's Range	16.00 - 16.40
52-Week Range	12.90 - 33.40
Beta	-0.11
RSI	51.41
Earnings Date	Apr 10, 2026

About Bio-View

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company’s products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies var...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 31
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BIOV

Financial Performance

In 2025, Bio-View's revenue was 19.93 million, a decrease of -22.32% compared to the previous year's 25.66 million. Losses were -15.33 million, 387.0% more than in 2024.